THLD Threshold Pharmaceuticals, Inc. featured news, full reports, and detailed charts
Threshold Pharmaceuticals, Inc. (THLD) Wrap Up:
We are a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of solid tumors is characterized by, among other things, hypoxia or lack of oxygen, disordered angiogenesis, and the upregulation of glucose transport. This hypoxic environment is known to be resistant to standard chemotherapy 3 -------------------------------------------------------------------------------- Table of Contents and radiation. It is thought to be responsible for the poor prognosis of many solid tumors and treating the hypoxic environment is currently believed to be a significant unmet medical need. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f12%2f0001193125-08-054250.html#FIS_BUSINESS"Threshold Pharmaceuticals Inc. (THLD:NASDAQ)
Snapshot of Threshold Pharmaceuticals Inc. (THLD)
|
OPEN
$2.01
|
PREVIOUS CLOSE
$1.98
|
|
|
DAY HIGH
$2.03
|
DAY LOW
$1.87
|
|
|
52 WEEK HIGH
10/12/09 - $3.87
|
52 WEEK LOW
11/25/08 - $0.34
|
|
|
MARKET CAP
68.1M
|
AVERAGE VOLUME 3 mo
149.0K
|
|
|
DILUTED EPS TTM
$-1.55
|
SHARES OUTSTANDING
33.6M
|
|
|
THLD Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
THLD Top Compensated Officers
Executives, Board Directors
Key developments for Threshold Pharmaceuticals Inc. (THLD)
Threshold Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported loss from operations of $5.2 million and net loss of $6.1 million or $0.40 loss per basic and diluted share compared to loss from operations of $4.6 million and net loss of $4.5 million or $0.49 loss per basic and diluted share for the same period a year ago. For the nine months, the company reported loss from operations of $15.8 million and net loss of $18.9 million or $1.24 loss per basic and diluted share compared to loss from operations of $13.8 million and net loss of $13.4 million or $1.86 loss per basic and diluted share for the same period a year ago.
Threshold Pharmaceuticals Inc. expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on October 30, 2009).
Threshold Pharmaceuticals Inc. - Conference Presentation Calls
THLD Competitors
| Company | Last | Change |
| VaxGen Inc | $0.62 USD | +0.01 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | THLD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 85.9x |
|
| Price/Book | 8.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 165.7x |
|
|
THLD |
||
THLD transactions
| Type Date |
Target |
|
Private Placement
September 30, 2009 |
-- |